Westfield Capital Management
ALXN

Westfield Capital Management’s Alexion Pharmaceuticals ALXN Stock Holding History

Westfield Capital Management’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-288,329
Closed -$40.1M – 280
2018
Q3 		$40.1M Buy
288,329
+51,744
+22% +$6.49M 0.28% 119
2018
Q2 		$29.4M Sell
236,585
-2,495
-1% -$292K 0.22% 150
2018
Q1 		$26.6M Buy
+239,080
New +$28.6M 0.21% 156
2017
Q4 		– Sell
-453,167
Closed -$63.6M – 274
2017
Q3 		$63.6M Buy
453,167
+121,897
+37% +$16.6M 0.49% 73
2017
Q2 		$40.3M Sell
331,270
-27,942
-8% -$3.25M 0.34% 105
2017
Q1 		$43.6M Buy
+359,212
New +$46.3M 0.37% 94

Other funds holding ALXN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Westfield Capital Management's ALXN Position: Q4 2018 in Review

Westfield Capital Management sold out of Alexion Pharmaceuticals (ALXN) in Q4 2018, closing a stake of 288,329 shares — an estimated $40.1M sold.

Westfield Capital Management first reported a position in ALXN in Q1 2017 and held it in 6 quarters. The position peaked at $63.6M in Q3 2017. 608 funds tracked by Wall St. Rank hold ALXN as of Q4 2018.

  • Westfield Capital Management reported no remaining Alexion Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
  • Westfield Capital Management sold 288,329 Alexion Pharmaceuticals shares in Q4 2018, an estimated $40.1M.
  • Westfield Capital Management first reported a position in Alexion Pharmaceuticals in Q1 2017 and held it in 6 quarters.
  • Westfield Capital Management's Alexion Pharmaceuticals position peaked at $63.6M in Q3 2017.
  • 608 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q4 2018.

Based on Westfield Capital Management's 13F filing for Q4 2018, filed 8 Feb 2019.